John-Arne Røttingen

John-Arne Røttingen's AcademicInfluence.com Rankings

John-Arne Røttingen

Philosophy

#10658

World Rank

#14624

Historical Rank

Logic

#7745

World Rank

#9595

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Why Is John-Arne Røttingen Influential?

(Suggest an Edit or Addition)

According to Wikipedia, John-Arne Røttingen is a Norwegian medical scientist, research administrator and civil servant. He is currently Ambassador for Global Health in the Norwegian Ministry of Foreign Affairs, and has been a special advisor to the World Health Organization . 11 October 2023 Røttingen was named the new head of the Wellcome Trust.

(See a Problem?)

John-Arne Røttingen's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results (2020) (2026)
Access to effective antimicrobials: a worldwide challenge (2016) (800)
Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!) (2017) (716)
Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial (2015) (685)
Mapping of available health research and development data: what's there, what's missing, and what role is there for a global observatory? (2013) (271)
Treatment options for visceral leishmaniasis: a systematic review of clinical studies done in India, 1980-2004. (2005) (233)
Binding of Human Factor VIIa to Tissue Factor Induces Cytosolic Ca2+ Signals in J82 Cells, Transfected COS-1 Cells, Madin-Darby Canine Kidney Cells and in Human Endothelial Cells Induced to Synthesize Tissue Factor (*) (1995) (207)
Coagulation Factors VIIa and Xa Induce Cell Signaling Leading to Up-regulation of the egr-1 Gene* (1999) (184)
Estimating the cost of vaccine development against epidemic infectious diseases: a cost minimisation study (2018) (168)
Quasi-experimental study designs series-paper 4: uses and value. (2017) (165)
Metaanalysis and Metaregression in Interpreting Study Variability in the Impact of Sexually Transmitted Diseases on Susceptibility to HIV Infection (2005) (161)
Evaluating health systems strengthening interventions in low-income and middle-income countries: are we asking the right questions? (2012) (149)
Coagulation Factors VII and X Induce Ca2+ Oscillations in Madin-Darby Canine Kidney Cells Only When Proteolytically Active* (1996) (147)
Exploring the evidence base for national and regional policy interventions to combat resistance (2016) (146)
Maximising access to achieve appropriate human antimicrobial use in low-income and middle-income countries (2016) (132)
International cooperation to improve access to and sustain effectiveness of antimicrobials (2016) (128)
What level of domestic government health expenditure should we aspire to for universal health coverage? (2017) (122)
The ring vaccination trial: a novel cluster randomised controlled trial design to evaluate vaccine efficacy and effectiveness during outbreaks, with special reference to Ebola (2015) (120)
Guidance for Evidence-Informed Policies about Health Systems: Rationale for and Challenges of Guidance Development (2012) (120)
Guidance for Evidence-Informed Policies about Health Systems: Linking Guidance Development to Policy Development (2012) (117)
Trends in Health Policy and Systems Research over the Past Decade: Still Too Little Capacity in Low-Income Countries (2011) (98)
Ruled by waves? Intracellular and intercellular calcium signalling. (2000) (98)
Association between environmental risk factors and campylobacter infections in Sweden (2004) (92)
An international legal framework to address antimicrobial resistance (2015) (88)
Practical tools and methods for health technology assessment in Europe: Structures, methodologies, and tools developed by the European network for Health Technology Assessment, EUnetHTA (2009) (84)
CEPI—a new global R&D organisation for epidemic preparedness and response (2017) (80)
Inclusion of quasi-experimental studies in systematic reviews of health systems research. (2015) (79)
The Joint Action and Learning Initiative: Towards a Global Agreement on National and Global Responsibilities for Health (2011) (75)
Developing Health Technology Assessment to address health care system needs. (2010) (75)
Strategies for achieving global collective action on antimicrobial resistance (2015) (70)
Antimicrobial resistance: The complex challenge of measurement to inform policy and the public (2017) (66)
UN High-Level Meeting on antimicrobials—what do we need? (2016) (65)
New Vaccines against Epidemic Infectious Diseases. (2017) (65)
Risk factors associated with typhoid fever in Son La province, northern Vietnam. (2005) (62)
Guidance for Evidence-Informed Policies about Health Systems: Assessing How Much Confidence to Place in the Research Evidence (2012) (57)
Background Paper on Conceptual Issues Related to Health Systems Research to Inform a WHO Global Strategy on Health Systems Research (2012) (56)
Cutting Edge: T Cell-Specific Adapter Protein Inhibits T Cell Activation by Modulating Lck Activity (2000) (54)
Shared Responsibilities for Health: A Coherent Global Framework for Health Financing. Final Report of the Centre on Global Health Security Working Group on Health Financing (2014) (54)
Rocuronium and anaphylaxis – a statistical challenge (2001) (52)
Open Source Drug Discovery in Practice: A Case Study (2012) (52)
Quasi-experimental study designs series-paper 1: introduction: two historical lineages. (2017) (47)
Waterborne outbreak of gastroenteritis in a religious summer camp in Norway, 2002 (2004) (43)
Definition and estimation of an actual reproduction number describing past infectious disease transmission: application to HIV epidemics among homosexual men in Denmark, Norway and Sweden (2004) (43)
Global public goods for health: weaknesses and opportunities in the global health system (2017) (43)
Health technology assessment to optimize health technology utilization: Using implementation initiatives and monitoring processes (2010) (43)
Diagnostic preparedness for infectious disease outbreaks (2017) (42)
Delinking Investment in Antibiotic Research and Development from Sales Revenues: The Challenges of Transforming a Promising Idea into Reality (2016) (41)
Conceptual and institutional gaps: understanding how the WHO can become a more effective cross-sectoral collaborator (2015) (41)
A New Deal for Global Health R&D? The Recommendations of the Consultative Expert Working Group on Research and Development (CEWG) (2012) (39)
On the mechanisms of the growth‐promoting effect of prostaglandins in hepatocytes: The relationship between stimulation of DNA synthesis and signaling mediated by adenylyl cyclase and phosphoinositide‐specific phospholipase C (1995) (39)
National and Global Responsibilities for Health (2010) (36)
Split WHO in Two: Strengthening Political Decision-Making and Securing Independent Scientific Advice (2014) (36)
Economic Incentives for Antibacterial Drug Development: Literature Review and Considerations From the Transatlantic Task Force on Antimicrobial Resistance. (2016) (36)
Assessing Proposals for New Global Health Treaties: An Analytic Framework. (2015) (35)
A Global Biomedical R&D Fund and Mechanism for Innovations of Public Health Importance (2015) (35)
Assessing the Expected Impact of Global Health Treaties: Evidence From 90 Quantitative Evaluations. (2015) (34)
Synchronized Ca2+ oscillations induced in Madin Darby canine kidney cells by bradykinin and thrombin but not by ATP. (1997) (32)
A multinational Delphi consensus to end the COVID-19 public health threat (2022) (31)
Securing the public good of health research and development for developing countries. (2012) (31)
Twelve myths about systematic reviews for health system policymaking rebutted (2013) (31)
Phagocytic dendritic cells from myelomas activate tumor-specific T cells at a single cell level. (2001) (30)
Where is the policy in health policy and systems research agenda? (2015) (30)
Assessing Implementation Mechanisms for an International Agreement on Research and Development for Health Products (2012) (30)
Study-design selection criteria in systematic reviews of effectiveness of health systems interventions and reforms: A meta-review. (2012) (29)
Cellular Consequences of the Initiation of Blood Coagulation (1999) (28)
New approaches to WHO financing: the key to better health (2018) (28)
Introduction and geographic availability of new antibiotics approved between 1999 and 2014 (2018) (28)
Advancing the field of health systems research synthesis (2015) (27)
The Joint Action and Learning Initiative on National and Global Responsibilities for Health (2010) (27)
Growth‐promoting effects of Ca2+‐mobilizing agents in hepatocytes: Lack of correlation between the acute activation of phosphoinositide‐specific phospholipase C and the stimulation of DNA synthesis by angiotensin II, vasopressin, norepinephrine, and prostaglandin F2α (1996) (27)
Changing mindsets in health policy and systems research (2013) (26)
Global, synchronous oscillations in cytosolic calcium and adherence in bradykinin-stimulated Madin-Darby canine kidney cells. (2004) (26)
Common characteristics of open source software development and applicability for drug discovery: a systematic review (2011) (25)
Developing vaccines against epidemic-prone emerging infectious diseases (2019) (25)
Supporting tough decisions in Norway: A healthcare system approach (2010) (25)
The impact of an intervention programme employing a hands-on technique to reduce the incidence of anal sphincter tears: interrupted time-series reanalysis (2013) (25)
Evidence Synthesis International (ESI): Position Statement (2020) (24)
Are the Norwegian health research investments in line with the disease burden? (2014) (24)
Pharyngeal carriage of Neisseria meningitidis in 2-19-year-old individuals in Uganda. (2006) (23)
The need for global R&D coordination for infectious diseases with epidemic potential (2016) (23)
A Global Antimicrobial Conservation Fund for Low- and Middle-Income Countries. (2016) (23)
Dark Sides of the Proposed Framework Convention on Global Health's Many Virtues: A Systematic Review and Critical Analysis (2013) (23)
A Review of Conceptual Barriers and Opportunities facing Health Systems Research to inform a Strategy from the World Health Organization (2012) (22)
Measuring the risk of HIV transmission. (2001) (22)
Quantitative analysis of cytosolic free calcium oscillations in neutrophils by mathematical modelling. (1994) (21)
INTERACTION INITIATIVES BETWEEN REGULATORY, HEALTH TECHNOLOGY ASSESSMENT AND COVERAGE BODIES, AND INDUSTRY (2012) (21)
Towards a coherent global framework for health financing: recommendations and recent developments (2017) (21)
International Law Has a Role to Play in Addressing Antibiotic Resistance (2015) (21)
Stability of a Vesicular Stomatitis Virus-Vectored Ebola Vaccine. (2016) (21)
Pull Incentives for Antibacterial Drug Development: An Analysis by the Transatlantic Task Force on Antimicrobial Resistance (2017) (21)
Effi cacy and eff ectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein : interim results from the Guinea ring vaccination cluster-randomised trial (2015) (20)
Immunogenicity of Fractional Doses of Tetravalent A/C/Y/W135 Meningococcal Polysaccharide Vaccine: Results from a Randomized Non-Inferiority Controlled Trial in Uganda (2008) (20)
Examining the Global Health Arena: Strengths and Weaknesses of a Convention Approach to Global Health Challenges (2010) (19)
Intercellular calcium signalling in cultured renal epithelia: a theoretical study of synchronization mode and pacemaker activity (2004) (18)
Using European travellers as an early alert to detect emerging pathogens in countries with limited laboratory resources (2007) (18)
What are the effects of HTA reports on the health system? Evidence from the research literature. (2008) (18)
Developing an approach to assessing the political feasibility of global collective action and an international agreement on antimicrobial resistance (2016) (17)
Development Assistance for Health: Quantitative Allocation Criteria and Contribution Norms (2014) (17)
Wiring a nation: putting knowledge into action (2010) (17)
Development assistance for health (2018) (17)
Insights into early stage of antibiotic development in small- and medium-sized enterprises: a survey of targets, costs, and durations (2018) (16)
The Global Innovation Model for Antibiotics Needs Reinvention (2015) (16)
Producing and using timely comparative evidence on drugs: lessons from clinical trials for covid-19 (2020) (15)
Development assistance for health: what criteria do multi- and bilateral funders use? (2017) (13)
Emerging Salmonella Enteritidis anaerogenic phage type 14b: outbreak in Norwegian, Swedish and Finnish travellers returning from Greece. (2006) (13)
Quasi-experimental study designs series-paper 13: realizing the full potential of quasi-experiments for health research. (2017) (13)
Global trends in health research and development expenditures – the challenge of making reliable estimates for international comparison (2015) (13)
Projected Treatment Capacity Needs in Sierra Leone (2014) (13)
Towards a new global business model for antibiotics: delinking revenues from sales. (2015) (13)
Global health financing towards 2030 and beyond (2017) (12)
The challenge of middle-income countries to development assistance for health: recipients, funders, both or neither? (2017) (12)
Informing the establishment of the WHO Global Observatory on Health Research and Development: a call for papers (2015) (12)
International treaties have mostly failed to produce their intended effects (2022) (11)
Quasi-experimental study designs series-paper 12: strengthening global capacity for evidence synthesis of quasi-experimental health systems research. (2017) (11)
A roadmap for sustainably governing the global antimicrobial commons (2019) (11)
Global governance and the broader determinants of health: A comparative case study of UNDP’s and WTO’s engagement with global health (2018) (9)
[Parent assessment of outpatient child and adolescent mental health services]. (2008) (9)
An Open Source Business Model for Malaria (2015) (9)
Emerging Salmonella Enteritidis anaerogenic phage type 14b: Outbreak in Norwegian, Swedish and Finnish travellers returning from Greece. (2006) (9)
Accelerating clinical trial implementation in the context of the COVID-19 pandemic: challenges, lessons learned and recommendations from DisCoVeRy and the EU-SolidAct EU response group (2021) (9)
Future challenges for HTA in Europe. (2008) (9)
Humoral and cellular immune response induced by rVSVΔG-ZEBOV-GP vaccine among frontline workers during the 2013–2016 West Africa Ebola outbreak in Guinea (2020) (9)
New approaches to ranking countries for the allocation of development assistance for health: choices, indicators and implications (2018) (9)
Use of manual techniques for perineal support in Norwegian maternity departments. (2011) (8)
Antimicrobials: access and sustainable eff ectiveness 3 Maximising access to achieve appropriate human antimicrobial use in low-income and middle-income countries (2016) (8)
Antimicrobials: access and sustainable eff ectiveness 1 Access to eff ective antimicrobials: a worldwide challenge (2015) (8)
Alcohol control: Be sparing with international laws (2012) (8)
Reboot biomedical R&D in the global public interest (2022) (8)
Making sense of health estimates (2015) (8)
Global-health research architecture—time for mergers? (2009) (8)
[The hospital organization as the staff see it]. (2002) (7)
Measuring shape and motion of white blood cells from sequences of fluorescence microscopy images (1996) (7)
Effi cacy and eff ectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease : fi nal results from the Guinea ring vaccination , open-label , cluster-randomised trial ( Ebola Ça Suffi t ! ) (2017) (7)
Global platform to inform investments for health R&D (2016) (7)
Promoting Intersectoral Collaboration Through the Evaluations of Public Health Interventions: Insights From Key Informants in 6 European Countries (2020) (7)
[Cecal volvulus as a complication in Cornelia de Lange syndrome. A case report and literature review]. (1998) (6)
Governing Global Antimicrobial Resistance: 6 Key Lessons From the Paris Climate Agreement. (2022) (6)
Health creates welfare - the role of the health system in Norwegian society (2008) (6)
Health policy and systems research: building momentum and community (2014) (6)
International law’s effects on health and its social determinants: protocol for a systematic review, meta-analysis, and meta-regression analysis (2016) (6)
Allocating external financing for health: a discrete choice experiment of stakeholder preferences (2018) (6)
An antibiotic’s journey from marketing authorization to use, Norway (2017) (6)
Supply chain transparency and the availability of essential medicines (2021) (6)
Prophylaxis of venous thromboembolism by aspirin, warfarin and heparin in patients with hip fracture. A prospective clinical study with cost-benefit analysis. (1984) (6)
R&D for Emerging Infectious Diseases of Epidemic Potential: Sharing Risks and Benefits Through a New Coalition (2020) (6)
Questionable efficacy of the rVSV-ZEBOV Ebola vaccine – Authors' reply (2018) (6)
Antimicrobial Resistance in a One Health and One World Perspective – Mechanisms and Solutions (2017) (5)
[Assessment of community mental health centres by general practitioners]. (2006) (4)
Setting Strategic Objectives for the Coalition for Epidemic Preparedness Innovations: An Exploratory Decision Analysis Process (2019) (4)
Legen – homo economicus eller homo sociologicus? (2002) (4)
Antimicrobials: access and sustainable eff ectiveness 5 International cooperation to improve access to and sustain eff ectiveness of antimicrobials (2016) (4)
A framework convention on obesity control? (2011) (4)
How can knowledge brokering be better supported across European health system (2013) (4)
[Rarity--a separate criterion used in prioritization?]. (2014) (4)
[The physicians--homo economicus or homo sociologicus?]. (2002) (4)
The effect of generic market entry on antibiotic prescriptions in the United States (2021) (3)
Ebola vaccines – Where are we? (2016) (3)
Cost-effectiveness of cochlear implantation in adults (2006) (3)
Speeding up epidemic emergency response. (2015) (3)
Financing and collaboration on research and development for nodding syndrome (2016) (3)
Distributing development assistance for health: simulating the implications of 11 criteria (2017) (3)
Should Antibiotics Be Controlled Medicines? Lessons from the Controlled Drug Regimen (2018) (3)
[Physicians and research--when is the lowest point reached?]. (2003) (3)
[Open processes for prioritization]. (2010) (2)
Global health governance after 2015 (2013) (2)
Options for improving malaria treatment: Introduction (2010) (2)
Efficacy and safety of baricitinib in hospitalized adults with severe or critical COVID-19 (Bari-SolidAct): a randomised, double-blind, placebo-controlled phase 3 trial (2023) (2)
Supra‐SAC: Need and Role for an All‐of‐Government Scientific Advisory Committee (2018) (2)
[Recruitment of students for medical research]. (1998) (2)
Global Challenges: Global Health (2015) (2)
Financing open-access publication after 2024 (2019) (2)
The idea of a convention for global health. (2011) (2)
Eﬃ cacy and eﬀ ectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: ﬁ nal results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suﬃ t!) (2017) (2)
Chapter 8 Knowledge brokering in Norway : bringing rigour and transparency to policy inputs (2014) (2)
Human resources for health: time to move out of crisis mode (2016) (2)
Targeted health innovation for global health (2019) (2)
Measuring Shape and Motion of White Blood Cellsfrom Sequences of Fluorescence Microscopy (2007) (1)
Effective international collaboration to improve access to and sustain effectiveness of antimicrobials (2015) (1)
How can knowledge brokering be advancedin a country’s health system? (2013) (1)
[Development of infectious diseases--a consequence of differences?]. (2001) (1)
Global biomedical R&D expenditures. (2014) (1)
[Resource to medical research should be doubled]. (2005) (1)
Governance Arrangements for Health R&D (2014) (1)
[Environmental pollutants with hormonal effects. Is estrogen theory a good model?]. (1997) (1)
Global health--a challenge for us all. (2011) (1)
[Challenges for professional development and research in general practice]. (2004) (1)
Efficacy and Safety of Baricitinib for the Treatment of Hospitalized Adults with Severe or Critical COVID-19 (Bari-SolidAct): A Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Trial (2022) (1)
Correction to: Developing vaccines against epidemic-prone emerging infectious diseases (2020) (1)
[Medical research at Norwegian universities]. (1998) (1)
Helse i en globalisert verden (2003) (1)
Evaluating official development assistance-funded granting mechanisms for global health and development research that is initiated in high-income countries (2022) (1)
Global Challenges – an innovative journal for tackling humanity's major challenges (2015) (1)
Ebola vaccine trial in Guinea (2015) (1)
Transferable exclusivity voucher: a flawed incentive to stimulate antibiotic innovation (2023) (1)
single cell level Phagocytic dendritic cells from myelomas activate tumor-specific T cells at a (2013) (0)
[Grants--length of employment and duty to work]. (1995) (0)
[Local and global environmental medicine--assessment by Norwegian physicians]. (2002) (0)
The economics of new international health laws (2012) (0)
Enrichment process, the rich in polyunsaturated fatty acids and phospholipid and application of this enriched fat. (1990) (0)
[Medical education--ready to fall down?]. (1993) (0)
Edinburgh Research Explorer Evidence Synthesis International (ESI): Position Statement (2020) (0)
[Norwegian public health in a "greenhouse". An example of health effects caused by global environmental problems]. (1997) (0)
[A. Heiberg and colleagues reply]. (2014) (0)
Society for Social Medicine and the International Epidemiological Association European Group (2001) (0)
Event working paper 1 : priority setting for health R&D (2013) (0)
ACT-A: half empty or half full? (2022) (0)
[Health in the global world]. (2003) (0)
[Medical research at Norwegian universities. Recruitment crisis when it comes to basic fields]. (1998) (0)
[Evaluation of medical students during basic training]. (1995) (0)
[Recruitment problems in medical research?]. (1997) (0)
Shared responsibilities for health: a new global framework for sustainable health financing (2014) (0)
[Mammography screening of women in their forties]. (2007) (0)
Erratum (1982) (0)
[Not exactly accurate about salaries to fellowship recipients]. (1997) (0)
Insights into early stage of antibiotic development in small- and medium-sized enterprises: a survey of targets, costs, and durations (2018) (0)
Implementation of a centralized pharmacovigilance system in academic pan‐European clinical trials: Experience from EU‐Response and conect4children consortia (2023) (0)
Accelerating clinical trial implementation in the context of the COVID-19 pandemic: author's response (2022) (0)
Ingen er trygge før alle er trygge (2020) (0)
Title Norwegian Cardiovascular Disease Model ( NorCaD ) – a simulation model for estimating health benefits and cost consequences of cardiovascular interventions Institution Norwegian Knowledge Centre for the Health Services ( NOKC ) (2008) (0)
Correspondence: Alcohol Control: Be Sparing with International Laws (2012) (0)
En delt verden (2003) (0)
Two years with cOAlition S (2020) (0)
Correspondence: Global Health Governance after 2015 (2013) (0)
[Power distribution and knowledge]. (2005) (0)
The impact of an interventional program employing a hands-on technique to reduce the incidence of anal sphincter tears : An interrupted time-series re-analysis ( study protocol ) (2013) (0)
[Independence of the Knowledge Center when it comes to drug information]. (2005) (0)
[The knowledge center and the HPV vaccine]. (2007) (0)

This paper list is powered by the following services:

Other Resources About John-Arne Røttingen

en.wikipedia.org

What Schools Are Affiliated With John-Arne Røttingen?

John-Arne Røttingen is affiliated with the following schools:

John-Arne Røttingen's Academic­Influence.com Rankings